These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12460033

  • 1. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ.
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [Abstract] [Full Text] [Related]

  • 2. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 3. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 6. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.
    N Engl J Med; 1998 Aug 27; 339(9):584-90. PubMed ID: 9718377
    [Abstract] [Full Text] [Related]

  • 7. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS, Fishbane S, Elzein H, Lynn RI, Deoreo PB, Tharpe DL, Meisels IS.
    Hemodial Int; 2005 Jul 27; 9(3):255-63. PubMed ID: 16191075
    [Abstract] [Full Text] [Related]

  • 8. Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient.
    Collins A, Ellefson J.
    Nephrol Nurs J; 2000 Apr 27; 27(2):233-6. PubMed ID: 11111551
    [Abstract] [Full Text] [Related]

  • 9. Anemia management and treatment response in patients on hemodialysis: the MAR study.
    Portolés J, López-Gómez JM, Aljama P.
    J Nephrol; 2006 Apr 27; 19(3):352-60. PubMed ID: 16874697
    [Abstract] [Full Text] [Related]

  • 10. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ.
    Nephrol Dial Transplant; 2003 Jun 27; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [Abstract] [Full Text] [Related]

  • 11. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M.
    Nephrol Dial Transplant; 2005 Oct 27; 20(10):2146-52. PubMed ID: 15985516
    [Abstract] [Full Text] [Related]

  • 12. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar 27; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

  • 13. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
    Wong CF, McCarthy M, Howse ML, Williams PS.
    Ren Fail; 2007 Mar 27; 29(6):653-9. PubMed ID: 17763158
    [Abstract] [Full Text] [Related]

  • 14. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct 27; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 15. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.
    Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J.
    J Clin Epidemiol; 2004 Oct 27; 57(10):1086-95. PubMed ID: 15528060
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ, Carey P, Johnson CA.
    Am J Hosp Pharm; 1992 Jun 27; 49(6):1451-4. PubMed ID: 1529988
    [Abstract] [Full Text] [Related]

  • 17. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
    Abbas EE, Afioni N, Al Wakeel J, Bakr MA, Dham R, Donia A, Droubi N, Khidir E, Mathew CM, Mitwali AH, Naga S, Pingle A, Rashed A, Roshdy A, Shaheen F, Shaibani B, Shaibani FM, Shaker DS, Sheiban A, Solieman M.
    Transplant Proc; 2004 Jun 27; 36(6):1805-11. PubMed ID: 15350482
    [Abstract] [Full Text] [Related]

  • 18. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States.
    Stack AG.
    Am J Kidney Dis; 2003 Feb 27; 41(2):310-8. PubMed ID: 12552491
    [Abstract] [Full Text] [Related]

  • 19. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA.
    Pharmacoepidemiol Drug Saf; 2009 Oct 27; 18(10):932-40. PubMed ID: 19572312
    [Abstract] [Full Text] [Related]

  • 20. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
    Thitiarchakul S, Tasanarong A.
    J Med Assoc Thai; 2007 Apr 27; 90(4):636-42. PubMed ID: 17487116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.